
Victor N Sakran
Examiner (ID: 15805)
| Most Active Art Unit | 3507 |
| Art Unit(s) | 3507, 3505, 3677, 3626, 2899 |
| Total Applications | 3429 |
| Issued Applications | 3196 |
| Pending Applications | 92 |
| Abandoned Applications | 141 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17274505
[patent_doc_number] => 20210380703
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => ACVR2A-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/394228
[patent_app_country] => US
[patent_app_date] => 2021-08-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50097
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17394228
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/394228 | ACVR2A-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF | Aug 3, 2021 | Abandoned |
Array
(
[id] => 17213146
[patent_doc_number] => 20210346482
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => SUBSTANCES, VACCINES AND METHODS FOR DIAGNOSING AND REDUCING INCIDENCES OF TRANSPLANT REJECTION
[patent_app_type] => utility
[patent_app_number] => 17/380477
[patent_app_country] => US
[patent_app_date] => 2021-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18957
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17380477
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/380477 | SUBSTANCES, VACCINES AND METHODS FOR DIAGNOSING AND REDUCING INCIDENCES OF TRANSPLANT REJECTION | Jul 19, 2021 | Abandoned |
Array
(
[id] => 17214563
[patent_doc_number] => 20210347900
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => ANTIBODIES SPECIFIC FOR LOX1 AND USE IN TREATMENT OF CARDIOVASCULAR DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/377863
[patent_app_country] => US
[patent_app_date] => 2021-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50132
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 169
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17377863
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/377863 | ANTIBODIES SPECIFIC FOR LOX1 AND USE IN TREATMENT OF CARDIOVASCULAR DISORDERS | Jul 15, 2021 | Abandoned |
Array
(
[id] => 19187852
[patent_doc_number] => 20240166765
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-23
[patent_title] => INFLAMMATORY DISEASE TREATMENT USING ANTI-TISSUE FACTOR ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/015532
[patent_app_country] => US
[patent_app_date] => 2021-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 89629
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18015532
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/015532 | INFLAMMATORY DISEASE TREATMENT USING ANTI-TISSUE FACTOR ANTIBODIES | Jul 9, 2021 | Pending |
Array
(
[id] => 18628251
[patent_doc_number] => 20230287105
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => METHODS FOR TREATING CARDIOVASCULAR DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/015444
[patent_app_country] => US
[patent_app_date] => 2021-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31999
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18015444
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/015444 | METHODS FOR TREATING CARDIOVASCULAR DISEASE | Jul 8, 2021 | Pending |
Array
(
[id] => 17369975
[patent_doc_number] => 20220025027
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-27
[patent_title] => ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/305413
[patent_app_country] => US
[patent_app_date] => 2021-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33455
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17305413
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/305413 | ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF | Jul 6, 2021 | Abandoned |
Array
(
[id] => 17369974
[patent_doc_number] => 20220025026
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-27
[patent_title] => ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/305412
[patent_app_country] => US
[patent_app_date] => 2021-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33453
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17305412
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/305412 | ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF | Jul 6, 2021 | Abandoned |
Array
(
[id] => 19396171
[patent_doc_number] => 12070500
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-27
[patent_title] => Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis
[patent_app_type] => utility
[patent_app_number] => 17/362020
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 43
[patent_figures_cnt] => 43
[patent_no_of_words] => 30131
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 121
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17362020
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/362020 | Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis | Jun 28, 2021 | Issued |
Array
(
[id] => 17443811
[patent_doc_number] => 20220064316
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => TREATMENT OF CANCER USING HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 17/359211
[patent_app_country] => US
[patent_app_date] => 2021-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 121885
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17359211
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/359211 | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor | Jun 24, 2021 | Issued |
Array
(
[id] => 17154820
[patent_doc_number] => 20210315871
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-14
[patent_title] => METHODS FOR TREATING AORTIC VALVE STENOSIS WITH A HEDGEHOG PATHWAY INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 17/354648
[patent_app_country] => US
[patent_app_date] => 2021-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5429
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17354648
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/354648 | METHODS FOR TREATING AORTIC VALVE STENOSIS WITH A HEDGEHOG PATHWAY INHIBITOR | Jun 21, 2021 | Abandoned |
Array
(
[id] => 18770885
[patent_doc_number] => 20230365687
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => ANTI-CD2 ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/012089
[patent_app_country] => US
[patent_app_date] => 2021-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61199
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18012089
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/012089 | ANTI-CD2 ANTIBODIES | Jun 21, 2021 | Pending |
Array
(
[id] => 18672955
[patent_doc_number] => 20230310409
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => TREATING RHEUMATOID ARTHRITIS
[patent_app_type] => utility
[patent_app_number] => 18/011884
[patent_app_country] => US
[patent_app_date] => 2021-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4508
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18011884
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/011884 | TREATING RHEUMATOID ARTHRITIS | Jun 20, 2021 | Pending |
Array
(
[id] => 17990205
[patent_doc_number] => 20220356242
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/348949
[patent_app_country] => US
[patent_app_date] => 2021-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 117463
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17348949
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/348949 | NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE | Jun 15, 2021 | Abandoned |
Array
(
[id] => 18717874
[patent_doc_number] => 11795205
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-24
[patent_title] => Heterodimeric Relaxin fusions polypeptides
[patent_app_type] => utility
[patent_app_number] => 17/348825
[patent_app_country] => US
[patent_app_date] => 2021-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 11
[patent_no_of_words] => 16061
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17348825
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/348825 | Heterodimeric Relaxin fusions polypeptides | Jun 15, 2021 | Issued |
Array
(
[id] => 17482275
[patent_doc_number] => 20220089779
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-24
[patent_title] => NME INHIBITORS AND METHODS OF USING NME INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/306477
[patent_app_country] => US
[patent_app_date] => 2021-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29001
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -57
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17306477
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/306477 | NME INHIBITORS AND METHODS OF USING NME INHIBITORS | May 2, 2021 | Abandoned |
Array
(
[id] => 17665311
[patent_doc_number] => 11358992
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-06-14
[patent_title] => Cell-penetrating cereblon recombinant fusion protein and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/244975
[patent_app_country] => US
[patent_app_date] => 2021-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 6269
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17244975
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/244975 | Cell-penetrating cereblon recombinant fusion protein and use thereof | Apr 29, 2021 | Issued |
Array
(
[id] => 18552151
[patent_doc_number] => 20230250160
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => BISPECIFIC PROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/997270
[patent_app_country] => US
[patent_app_date] => 2021-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11407
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997270
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/997270 | BISPECIFIC PROTEIN | Apr 28, 2021 | Pending |
Array
(
[id] => 17168878
[patent_doc_number] => 20210322548
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => METHODS AND COMPOSITIONS RELATING TO TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
[patent_app_type] => utility
[patent_app_number] => 17/239983
[patent_app_country] => US
[patent_app_date] => 2021-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17976
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17239983
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/239983 | Method for treating fibrosis with an anti-GDF-15 antibody | Apr 25, 2021 | Issued |
Array
(
[id] => 17185252
[patent_doc_number] => 20210332137
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => COMBINATION THERAPY FOR CANCER
[patent_app_type] => utility
[patent_app_number] => 17/224865
[patent_app_country] => US
[patent_app_date] => 2021-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23583
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17224865
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/224865 | COMBINATION THERAPY FOR CANCER | Apr 6, 2021 | Pending |
Array
(
[id] => 18337261
[patent_doc_number] => 20230129210
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-27
[patent_title] => BINDING PROTEINS USEFUL AGAINST ACE2-TARGETED VIRUSES
[patent_app_type] => utility
[patent_app_number] => 17/914000
[patent_app_country] => US
[patent_app_date] => 2021-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28240
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17914000
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/914000 | BINDING PROTEINS USEFUL AGAINST ACE2-TARGETED VIRUSES | Apr 4, 2021 | Pending |